LMLoreto Massardo

Loreto Massardo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Loreto Massardo has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of cognitive impairment, depression, disease activity, and disease damage on quality of life in women with systemic lupus erythematosus

    by J Calderón, P Flores, Jm Aguirre, G Valdivia, O Padilla, I Barra, L Scoriels, S Herrera, A González, L Massardo

    Objectives: To define the relative role of cognitive impairment, depression, disease activity, and disease damage in the decreased health-related quality of life (HRQoL) frequently observed in systemic lupus erythematosus (SLE) patients. Method: We studied 101 Chilean female SLE patients and applied the 12-item Medical Outcomes Study (MOS) Short Form Health Survey version 2 (SF-12v2) to assess HRQoL and the Cambridge Neuropsychological Test Automated Battery (CANTAB) to assess cognitive function. Analysis of covariance (ANCOVA) models included demographic and disease-related factors and cognitive function tests of sustained attention, memory, and executive function. Results: All measures of HRQoL were lower in the 101 female SLE patients compared to the women from the Chilean general population. HRQoL was associated with the following factors: (i) depression symptoms, which were detrimental to all components of the physical and mental HRQoL scores; (ii) executive dysfunction (spatial planning), which was associated with lower scores on role limitations due to physical health problems and emotional problems, and general health perceptions; (iii) higher activity and organ damage were deleterious to role physical, bodily pain, and physical summary scores; and (iv) higher damage also impacted physical function. Impairments in sustained attention and memory did not decrease the HRQoL. Conclusions: Our results highlight the relevance of executive dysfunction to poor physical and mental health components of HRQoL in SLE together with depression, while disease activity and disease damage are associated with lower HRQoL physical components. The need for cognitive function evaluation and rehabilitation in SLE is indicated.


  • Anti-N-methyl-D-aspartate receptor and anti-ribosomal-P autoantibodies contribute to cognitive dysfunction in systemic lupus erythematosus

    by L Massardo, M Bravo-Zehnder, J Calderón, P Flores, O Padilla, J M Aguirre, L Scoriels, A González

    Autoantibodies against N-methyl-D-aspartate receptor (anti-NMDAR) and ribosomal-P (anti-P) antigens are potential pathogenic factors in the frequently observed diffuse brain dysfunctions in patients with systemic lupus erythematosus (SLE). Although studies have been conducted in this area, the role of anti-NMDAR antibodies in SLE cognitive dysfunction remains elusive. Moreover, the specific contribution of anti-P antibodies has not been reported yet. The present study attempts to clarify the contribution of anti-NMDAR and anti-P antibodies to cognitive dysfunction in SLE. The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to assess a wide range of cognitive function areas in 133 Chilean women with SLE. ANCOVA models included autoantibodies, patient and disease features. Cognitive deficit was found in 20%. Higher SLEDAI-2K scores were associated with impairment in spatial memory and learning abilities, whereas both anti-NMDAR and anti-P antibodies contributed to deficits in attention and spatial planning abilities, which reflect fronto-parietal cortex dysfunctions. These results reveal an association of active disease together with specific circulating autoantibodies, such as anti-NMDAR and anti-P, with cognitive dysfunction in SLE patients.


  • Use of rituximab in Hispanic patients with severe ANCA associated vasculitis: A 6 years experience in a tertiary centre in Chile

    by F. Silva, L. Massardo, M. Mimica, P. Pastenes, M. Cisternas, F. Radrigan, M. Gutierrez

  • Hemorrhagic emergency due to intrahepatic aneurism rupture in a patient with Polyateritis Nodosa after long time of episodic fever: A case report

    by F. Silva, M. Cisternas, G. Maguida, M.I. Ruiz, P. Diaz, S. Gonzalez, J. Martinez, L. Meneses, L. Massardo

  • Open Access

    Early rheumatoid arthritis in Latin America: Low socioeconomic status related to high disease activity at baseline

    by Loreto Massardo, Bernardo A. Pons‐Estel, Daniel Wojdyla, Mario H. Cardiel, Claudio M. Galarza‐Maldonado, Mónica P. Sacnun, Enrique R. Soriano, Ieda M. Laurindo, Eduardo M. Acevedo‐Vásquez, Carlo V. Caballero‐Uribe, et al.

    Objective: To determine the influence of socioeconomic factors on disease activity in a Latin American (LA) early rheumatoid arthritis (RA) multinational inception cohort at baseline.Methods: Clinical evaluation, ethnicity, socioeconomic status (SES), 4‐variable Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28‐ESR), Health Assessment Questionnaire (HAQ) disability index (DI), and erosions were recorded in 1,093 patients with early RA (P < 0.01). When adjusted by country, the analysis of covariance model showed that low/low‐middle SES, female sex, partial coverage, and older age were associated with worse HAQ DI scores; only low/low‐middle SES was associated with higher DAS28 scores. Statistically significant differences were found in HAQ DI and DAS28 scores between countries. When excluding country, low/low‐middle SES, female sex, and no coverage were associated with worse HAQ DI and DAS28 scores, whereas separated/divorced/widowed status was associated with worse HAQ DI scores and age was associated with worse DAS28 scores. Logistic regression showed that older age, no coverage, and the Amerindian and other ethnic groups were associated with erosions.Conclusion: We compared early RA patients from the main LA ethnic groups. Our findings suggest that low/low‐middle SES is important in determining disease activity. A more genetic‐related background for erosions is possible.


  • Common mental disorders and psychological distress in systemic lupus erythematosus are not associated with disease activity

    by E Jarpa, M Babul, J Calderón, M González, Me Martínez, M Bravo-Zehnder, C Henríquez, S Jacobelli, A González, L Massardo

    Psychiatric diagnosis in patients with systemic lupus erythematosus (SLE) is controversial: variations have been reported in frequency, diagnostic assays, associations with disease activity, autoantibodies, and contributing social factors. Eighty-three consecutive non-selected Chilean patients with SLE were evaluated for: (i) 26 common mental disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), using the Mini-International Neuropsychiatric Interview (MINI-plus); (ii) psychological suffering measured by Hospital Anxiety and Depression Scale (HADS); (iii) ACR 1999 neuropsychiatric (NP)SLE criteria; (iv) SLE disease activity (SLEDAI-2K); (v) cumulative damage (SLICC/ACR); and (vi) anti-ribosomal P antibodies by enzyme-linked immunoassay and immunoblot. Psychiatric diagnoses occurred in 44.6% of patients; the most frequent (21.7%) was major depressive episode (MDE). No association with lupus activity was observed in patients with a DSM-IV diagnosis or MDE or psychological suffering. ACR 1999 NPSLE criteria were present in 42.2% of patients, the majority corresponding to mood (28.9%) or anxiety disorders (15.6%). Suicidal risk was present in 9.6% of patients. Anti-ribosomal P antibodies (13.3%) were not associated with DSM-IV diagnosis. Severe psychiatric disorders in SLE are common and not associated with disease activity.


  • Open Access

    Trombosis de senos venosos encefálicos como posible primera manifestación de enfermedad de Behçet: Caso clínico

    by Juan Carlos Lizarazo-Barrera, Sergio Jacobelli, Patricio Mellado, Sergio González, Loreto Massardo

    Behçet's disease (BD) is a systemic inflammatory vascular disease with several clinical manifestations and geographical differences in disease expression. In Middle Eastern countries it is one of the most common causes of cerebral venous thrombosis. We report a 29-year-old female admitted for acute headache and vomiting. A magnetic resonance image showed a large thrombosis of sagital and transverse sinuses. She developed oral and genital ulcers a week later. Ophthalmologic examination revealed left anterior uveitis and ipsilateral papilledema. Multiple studies ruled out a hypercoagulability syndrome. The patient used oral contraceptives. Anticoagulant therapy was prescribed. A biopsy of a genital ulcer demonstrated diffuse lymphocytic infiltration with vasculitis. After treatment with topical and systemic corticoids, her condition improved. Venous sinus thrombosis followed by oral and genital ulcers is an unusual presentation of Behçet's disease.


  • Open Access

    Artritis reumatoide temprana

    by Loreto Massardo

    Summary The rheumatoid arthritis is a chronic and disabling disease affecting large and small joints. The most important characteristic is the polyarthritis that typically affect initially hands, wrists and feet, affecting latter any synovial joint such as knees, ankles, elbows or shoulders. In this paper we highlight the importance of recognize early the disease to achieve a better therapeutic response, lesser disability, lesser day of work loses and to diminish the direct and indirect cost of the treatment.


  • Open Access

    Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context

    by E. R. Soriano, C. Galarza-Maldonado, M. H. Cardiel, B. A. Pons-Estel, L. Massardo, C. V. Caballero-Uribe, A. F. Achurra-Castillo, L. A. Barile-Fabris, J. Chávez-Corrales, J. F. Díaz-Coto, et al.

    GLADAR (Grupo Latino Americano de Estudio de Artritis Reumatoide) is a large group of Latin American (LA) rheumatologists experienced in the diagnosis and treatment of RA. In 2006, PANLAR and GLADAR published the first LA position paper on the pharmacological treatment of RA [1]. Since then, new therapies have emerged to help achieve the ultimate goal to preserve the patient's ability to function independently with an optimal quality of life.


  • Open Access

    Curso clínico de la nefropatía membranosa lúpica pura

    by Rolando Pastén V, Loreto Massardo V, Helmar Rosenberg G, Francisco Radrigán A, Emilio Roessler B, Andrés Valdivieso D, Sergio Jacobelli G

    The long-term outcome of the pure form of WHO type V lupus membranous glomerulonephritis is apparently more benign than that of other forms of lupus glomerulonephritis. However 12% of such patients progress to terminal renal failure. The presence of proteinuria may be an indication of cytotoxic agents. To study the clinical long-term outcome of WHO type V lupus membranous glomerulonephritis. A retrospective analysis of all kidney biopsies of a University Pathology Department, with the diagnosis of WHO type V lupus membranous glomerulonephritis. Review of medical records of patients with the disease and one clinical assessment of all living patients. Between 1973 and 2000, 703 kidney biopsies were done to patients with systemic lupus erythematosus. Of these, 40 were membranous glomerulonephritis and in 33 patients (28 women, age range 6-71 years), data on the evolution and survival was obtained. Nineteen had type Va and the rest type Vb nephritis. Two presented with renal failure and 11 with proteinuria over 3.5 g/24 h. The median follow-up since the renal biopsy was 63 months (range 1-316). At the end of follow-up, four had a creatinine clearance of less then 15 ml/h and four a clearance between 15 and 29 ml/h (one of these received a renal allograft). Eleven (33%) patients had died, mostly due to infections. Life expectancy at five years with a creatinine clearance over 15 ml/h was 75%. Bad prognostic factors were an elevated creatinine clearance over 15 ml/h was 75%. Bad prognostic factors were an elevated creatinine and high blood pressure at the moment of the biopsy. The clinical outcome of these patients was bad. Twelve percent reached a stage of terminal renal failure. This is in contrast with the 3% progression to a similar stage of proliferative glomerulonephritis treated with i.v. cyclophosphamide. New therapies for this condition must be sought.